OA
Omnio AB develops recombinant plasminogen therapeutics specifically for the treatment of diabetic foot ulcers (DFUs). This approach aims to enhance wound healing and reduce the risk of complications associated with DFUs.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Omnio AB develops recombinant plasminogen therapeutics specifically for the treatment of diabetic foot ulcers (DFUs). This approach aims to enhance wound healing and reduce the risk of complications associated with DFUs.